



**Australian Government**  
**Department of Health and Aged Care**  
 Therapeutic Goods Administration

**Public Summary**

|                                |  |                       |
|--------------------------------|--|-----------------------|
| <b>Summary for ARTG Entry:</b> | 340870   | PM+ Sleep + Calm Mind |
| <b>ARTG entry for</b>          | Medicine Listed  |                       |
| <b>Sponsor</b>                 | JSHealth Vitamins Pty Ltd  |                       |
| <b>Postal Address</b>          | 14/409 New South Head Road, Double Bay, Sydney, NSW, 2028<br>Australia |                       |
| <b>ARTG Start Date</b>         | 5/08/2020  |                       |
| <b>Product Category</b>        | Medicine   |                       |
| <b>Status</b>                  | Active   |                       |
| <b>Approval Area</b>           | Listed Medicines   |                       |

**Conditions**

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

**Products**

**1 . PM+ Sleep + Calm Mind**

|                     |                         |                       |            |
|---------------------|-------------------------|-----------------------|------------|
| <b>Product Type</b> | Single Medicine Product | <b>Effective Date</b> | 15/03/2022 |
|---------------------|-------------------------|-----------------------|------------|

**Permitted Indications**

- Maintain/support energy production
- Maintain/support bone health
- Maintain/support cardiovascular system health
- Maintain/support healthy cardiovascular system function
- Maintain/support heart health
- Maintain/support healthy muscle contraction function
- Maintain/support muscle function
- Maintain/support healthy neuromuscular system/function
- Maintain/support muscle relaxation
- Relieve irritability
- Calms the mind
- Aid/assist/helps mind relaxation
- Soothe/calm nerves
- Decrease/reduce/relieve nervous tension/unrest
- Decrease/reduce/relieve symptoms of mild anxiety
- Maintain/support nervous system health
- Maintain/support nervous system function
- Decrease/reduce/relieve disturbed/restless sleep

**Indication Requirements**

- Product presentation must not imply or refer to serious cardiovascular conditions.
- Product presentation must not imply or refer to mental illnesses, disorders or conditions.
- Label statement: If symptoms persist, talk to your health professional.
- Product presentation must not imply or refer to bone disease or disorders e.g. rheumatoid arthritis, juvenile arthritis, debilitating osteoarthritis, osteoporosis. Note: this requirement is not intended to apply where the indications referring to osteoporosis specified in column 2 of Table 2 of this instrument are also used.
- If product is indicated for weight loss, label statement: When used in conjunction with a program of reduced intake of dietary calories and increased physical activity.

Public Summary



**Australian Government**  
**Department of Health and Aged Care**  
 Therapeutic Goods Administration

Product presentation must only refer to mild anxiety.

Product presentation must not imply or refer to serious musculoskeletal or neurological conditions.

**Standard Indications**

No Standard Indications included on Record

**Specific Indications**

No Specific Indications included on Record

**Warnings**

No Warnings included on Record

**Additional Product information**

**Pack Size/Poison information**

**Pack Size**

**Poison Schedule**

**Components**

**1 . Formulation 1**

**Dosage Form**                      Tablet, film coated

**Route of Administration**      Oral

**Visual Identification**

**Active Ingredients**

|   |                  |
|---|------------------|
| <b>Lavender Oil</b>   | <b>81 mg</b>     |
| <b>magnesium amino acid chelate</b>                         | <b>100 mg</b>    |
| Equivalent: magnesium                                       | 20 mg            |
| <b>magnesium citrate</b>                                    | <b>507.52 mg</b> |
| Equivalent: magnesium                                       | 81 mg            |
| <b>magnesium glycinate</b>                                  | <b>359.2 mg</b>  |
| Equivalent: magnesium                                       | 50 mg            |
| <b>Matricaria chamomilla flower Extract dry concentrate</b> | <b>25 mg</b>     |
| Equivalent: Matricaria chamomilla (Dry)                     | 250 mg           |
| <b>Passiflora incarnata flower Extract dry concentrate</b>  | <b>250 mg</b>    |
| Equivalent: Passiflora incarnata (Dry)                      | 1.25 g           |

**Other Ingredients (Excipients)**

- calcium hydrogen phosphate dihydrate
- Carnauba Wax
- chlorophyllin-copper complex
- colloidal anhydrous silica
- croscarmellose sodium
- crospovidone
- hypromellose
- macrogol 400
- magnesium stearate
- maltodextrin
- microcrystalline cellulose
- povidone

Public Summary

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.